FDA Approves METHOTREXATE — Alembic Pharmaceuticals Inc.

Alembic Pharmaceuticals Inc. has gained final FDA approval to manufacture and market the oral generic version of Methotrexate Sodium, a pivotal approval that is expected to bolster the company’s established revenue streams following the expiration of the corresponding brand-name patent. This launch will intensify competition in the oral anti-rheumatic pharmacotherapy market.